Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
10x Genomics launches targeted gene expression solution » 09:05
05/20/20
05/20
09:05
05/20/20
09:05
TXG

10x Genomics

$78.24 /

+1.14 (+1.48%)

Building on its earlier…

Building on its earlier reveal at the Advances in Genome Biology and Technology General Meeting, 10x Genomics launched its Targeted Gene Expression Solution for single cell and shortly following for spatial genomic research. Targeted Gene Expression gives scientists the ability to focus their research on the cell types and biomarkers that matter most to their research, enabling them to answer biological questions quickly and efficiently. This approach also captures unique gene expression signatures, probes disease and drug targets and allows for the discovery of mechanisms through which small molecules act. Using this technology, researchers can measure the effects of activation or inhibition of signalling pathways. In addition, it also allows the scientific community to dissect signalling pathways using targeted CRISPR screens. 10x's Targeted Gene Expression Solution benefits from a list of comprehensive pre-designed gene panels that are relevant for different research areas, including cancer, immunology, neuroscience and various disease and drug targeting applications. This technology is also customizable for individualized research goals, improving experimental efficiency while maintaining high gene sensitivities. A 10x Custom Panel Designer, which will be released later this year, will enable customers to either add on genes to existing panels or create fully custom panels.

ShowHide Related Items >><<
TXG 10x Genomics
$78.24 /

+1.14 (+1.48%)

TXG 10x Genomics
$78.24 /

+1.14 (+1.48%)

05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
TXG 10x Genomics
$78.24 /

+1.14 (+1.48%)

TXG 10x Genomics
$78.24 /

+1.14 (+1.48%)

TXG 10x Genomics
$78.24 /

+1.14 (+1.48%)

Hot Stocks
10x Genomics deploys cohort-based COVID-19 employee testing » 09:15
05/19/20
05/19
09:15
05/19/20
09:15
TXG

10x Genomics

$77.10 /

-0.86 (-1.10%)

, ONEM

One Medical

$33.00 /

+0.96 (+3.00%)

10x Genomics (TXG) and…

10x Genomics (TXG) and One Medical (ONEM) announced the two organizations are partnering to pioneer a path toward the safe return to work by deploying a comprehensive approach to COVID-19 testing, digital employee symptom screening, and seamless access to remote and in-person care. 10x Genomics is the first of One Medical's more than 7,000 employer customers to begin executing a multi-pronged, cohort-based return to the workplace strategy. 10x Genomics added One Medical as a new healthcare benefit for its employees and began offering voluntary SARS-CoV-2 PCR tests to monitor for possible infection. As a part of the testing program, 10x Genomics has also teamed up with the Translational Genomics Research Institute, an affiliate of City of Hope, a non-profit medical institute working on COVID-19, for clinical testing of nasal swabs. Deemed an essential business, 10x Genomics has more than 50 academic labs, research institutes and pharmaceutical companies around the world using its products to make discoveries to accelerate the development of therapeutics, diagnostics and vaccines for battling COVID-19. These include the Vanderbilt Vaccine Center, where researchers are fast-tracking the development of antibody-based prophylaxis to protect people, particularly first responders and essential workers, who are at greatest risk of exposure to COVID-19; Merck, which is working on identifying new viral targets for potential COVID-19 therapeutics and vaccines; and multiple labs around the world conducting research into cellular mechanisms and immune responses to infection, and other aspects of COVID-19. To continue delivering its essential products and services, 10x Genomics partnered with One Medical to deploy its workplace reentry program, Healthy Together, to quickly operationalize an open-air testing site for COVID-19 PCR nasal swab collection tests at its Pleasanton headquarters. The nasal swab tests are sent to TGen's COVID-19 clinical laboratory for analysis. 10x Genomics already has over 150 employees from its R&D, manufacturing and IT groups enlisted in the program that are being regularly tested in cohorts. 10x Genomics plans to expand the program to cover more than 65 percent of its employee base.

ShowHide Related Items >><<
TXG 10x Genomics
$77.10 /

-0.86 (-1.10%)

ONEM One Medical
$33.00 /

+0.96 (+3.00%)

TXG 10x Genomics
$77.10 /

-0.86 (-1.10%)

05/12/20 Cowen
10x Genomics price target raised to $85 from $68 at Cowen
03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
ONEM One Medical
$33.00 /

+0.96 (+3.00%)

05/14/20 SunTrust
1Life Healthcare price target raised to $30 from $26 at SunTrust
05/14/20 Wells Fargo
1Life Healthcare price target raised to $23 from $18 at Wells Fargo
05/14/20 Piper Sandler
1Life Healthcare price target raised to $29 from $27 at Piper Sandler
02/25/20 Morgan Stanley
1Life Healthcare initiated with an Overweight at Morgan Stanley
TXG 10x Genomics
$77.10 /

-0.86 (-1.10%)

ONEM One Medical
$33.00 /

+0.96 (+3.00%)

TXG 10x Genomics
$77.10 /

-0.86 (-1.10%)

ONEM One Medical
$33.00 /

+0.96 (+3.00%)

TXG 10x Genomics
$77.10 /

-0.86 (-1.10%)

ONEM One Medical
$33.00 /

+0.96 (+3.00%)

Recommendations
10x Genomics price target raised to $85 from $68 at Cowen » 09:35
05/12/20
05/12
09:35
05/12/20
09:35
TXG

10x Genomics

$82.75 /

-0.2 (-0.24%)

Cowen analyst Doug…

Cowen analyst Doug Schenkel raised the firm's price target on 10x Genomics to $85 from $68 and keeps an Outperform rating on the shares. The analyst adjusted his estimated due to COVID but he sees continued success from its business model, strong underlying trends, and competitive positioning.

ShowHide Related Items >><<
TXG 10x Genomics
$82.75 /

-0.2 (-0.24%)

TXG 10x Genomics
$82.75 /

-0.2 (-0.24%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
TXG 10x Genomics
$82.75 /

-0.2 (-0.24%)

TXG 10x Genomics
$82.75 /

-0.2 (-0.24%)

TXG 10x Genomics
$82.75 /

-0.2 (-0.24%)

Earnings
10x Genomics reports Q1 EPS (22c), consensus (13c) » 16:24
05/11/20
05/11
16:24
05/11/20
16:24
TXG

10x Genomics

$82.36 /

-0.59 (-0.71%)

Reports Q1 revenue…

Reports Q1 revenue $71.91M, consensus $73.42M. "We are doing all we can to support our customers as they race to understand and fight the COVID-19 pandemic," said Serge Saxonov, co-founder and CEO of 10x Genomics. "Despite the temporary uncertainty in the macro environment, we see tremendous opportunities ahead. Our mission to accelerate the mastery of biology is more important now than it has ever been, and I am confident that the future holds an even greater appreciation and appetite for scientific discovery."

ShowHide Related Items >><<
TXG 10x Genomics
$82.36 /

-0.59 (-0.71%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
Earnings
10x Genomics withdraws previously announced FY 20 revenue guidance » 16:14
04/09/20
04/09
16:14
04/09/20
16:14
TXG

10x Genomics

$65.90 /

+1.82 (+2.84%)

Given the ongoing…

Given the ongoing uncertainty of the scope, duration and impact of the pandemic, 10x is currently unable to reasonably estimate its financial performance and is withdrawing its previously announced annual revenue guidance for 2020, which was issued on February 18. The company plans to provide final financial results and additional information related to the impact of COVID-19 on its upcoming earnings call, which is expected to be in early May.

ShowHide Related Items >><<
TXG 10x Genomics
$65.90 /

+1.82 (+2.84%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
Earnings
10x Genomics withdraws previously announced FY 20 revenue guidance » 16:14
04/09/20
04/09
16:14
04/09/20
16:14
TXG

10x Genomics

$65.90 /

+1.82 (+2.84%)

Given the ongoing…

Given the ongoing uncertainty of the scope, duration and impact of the pandemic, 10x is currently unable to reasonably estimate its financial performance and is withdrawing its previously announced annual revenue guidance for 2020, which was issued on February 18. The company plans to provide final financial results and additional information related to the impact of COVID-19 on its upcoming earnings call, which is expected to be in early May.

ShowHide Related Items >><<
TXG 10x Genomics
$65.90 /

+1.82 (+2.84%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
Earnings
10x Genomics sees Q1 revenue $71M- $72M, consensus $71.04M » 16:12
04/09/20
04/09
16:12
04/09/20
16:12
TXG

10x Genomics

$65.90 /

+1.82 (+2.84%)

Revenue for the first…

Revenue for the first quarter of 2020 is expected to be in the range of $71 to $72 million, an increase of 33% at the midpoint over the prior year period. As the pandemic spread from China to countries worldwide, the company saw a significant reduction in customer activity other than research related to the virus. Social distancing and stay-at-home orders have temporarily closed many academic and government labs. Consensus for Q1 revenue is $71.04M.

ShowHide Related Items >><<
TXG 10x Genomics
$65.90 /

+1.82 (+2.84%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
Over a quarter ago
Hot Stocks
10x Genomics appoints Kim Popovits to board of directors » 09:22
04/02/20
04/02
09:22
04/02/20
09:22
TXG

10x Genomics

$58.17 /

-4.25 (-6.81%)

10x Genomics announced…

10x Genomics announced the appointment of Kim Popovits, former Chairman of the Board, President and CEO of Genomic Health, Inc., to the company's Board of Directors.

ShowHide Related Items >><<
TXG 10x Genomics
$58.17 /

-4.25 (-6.81%)

03/11/20 JPMorgan
JPMorgan continues to recommend select exposure to Life Science Tools
03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
Recommendations
JPMorgan continues to recommend select exposure to Life Science Tools » 07:55
03/11/20
03/11
07:55
03/11/20
07:55
DHR

Danaher

$144.29 /

+2.26 (+1.59%)

, AVTR

Avantor

$13.83 /

+1.03 (+8.05%)

, PPD

PPD, Inc.

$27.34 /

+0.45 (+1.67%)

, IQV

Iqvia

$130.83 /

+6.6 (+5.31%)

, CTLT

Catalent

$47.53 /

+3.53 (+8.02%)

, ADPT

Adaptive Biotechnologies

$25.00 /

+0.2 (+0.81%)

, GH

Guardant Health

$67.87 /

-0.45 (-0.66%)

, NSTG

NanoString

$33.25 /

+1.91 (+6.09%)

, TXG

10x Genomics

$66.25 /

+0.925 (+1.42%)

Despite the year-to-date…

Despite the year-to-date correction in the Life Science Tools and Diagnostics space, valuations "remain healthy with a number of expected financial resets still to come," JPMorgan analyst Tycho Peterson tells investors in a research note. As such, the analyst continues to recommend select exposure names across the space. Peterson says Danaher (DHR), Avantor (AVTR), PPD, Inc. (PPD), Iqvia (IQV), Catalent (CTLT), Adaptive Biotechnologies (ADPT), Guardant Health (GH), NanoString (NSTG) and 10x Genomics (TXG). Medtech and tools are seeing the greatest impact to COVID-19, Peterson tells investors in a research note. The analyst remains cautious on the near-term outlook for companies with relatively high China exposure.

ShowHide Related Items >><<
DHR Danaher
$144.29 /

+2.26 (+1.59%)

03/03/20 Piper Sandler
Danaher unlikely to make competing bid for Qiagen, says Piper Sandler
02/03/20 Needham
Danaher price target raised to $187 from $167 at Needham
01/30/20 Piper Sandler
Danaher price target raised to $174 from $142 at Piper Sandler
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
AVTR Avantor
$13.83 /

+1.03 (+8.05%)

02/07/20 Cowen
Avantor weakness a buying opportunity, says Cowen
01/07/20 Wells Fargo
Wells Fargo initiates Life Science Tools, Services, Diagnostics Sector
01/07/20 Wells Fargo
Avantor initiated with an Overweight at Wells Fargo
PPD PPD, Inc.
$27.34 /

+0.45 (+1.67%)

03/03/20 Deutsche Bank
PPD, Inc. initiated with a Buy at Deutsche Bank
03/02/20 Jefferies
PPD, Inc. initiated with a Hold at Jefferies
03/02/20 JPMorgan
PPD, Inc. initiated with an Overweight at JPMorgan
03/02/20 Morgan Stanley
Morgan Stanley starts PPD, Inc. at Overweight with $34 price target
IQV Iqvia
$130.83 /

+6.6 (+5.31%)

03/03/20 Deutsche Bank
Iqvia initiated with a Buy at Deutsche Bank
02/20/20 Morgan Stanley
Veeva set up for 'clean' beat and raise Q4 report, says Morgan Stanley
02/14/20 Piper Sandler
Veeva initiated with an Overweight at Piper Sandler
02/13/20 JPMorgan
Iqvia price target raised to $195 from $180 at JPMorgan
CTLT Catalent
$47.53 /

+3.53 (+8.02%)

03/03/20
Fly Intel: Top five analyst initiations
03/03/20 Deutsche Bank
Catalent initiated with a Hold at Deutsche Bank
02/04/20 Baird
Catalent price target raised to $67 from $60 at Baird
02/04/20 Morgan Stanley
Catalent price target raised to $67 from $64 at Morgan Stanley
ADPT Adaptive Biotechnologies
$25.00 /

+0.2 (+0.81%)

11/13/19 JPMorgan
Adaptive Biotechnologies still has upside potential despite rally, says JPMorgan
07/23/19
Fly Intel: Top five analyst initiations
07/23/19 BTIG
Adaptive Biotechnologies initiated with a Buy at BTIG
GH Guardant Health
$67.87 /

-0.45 (-0.66%)

02/21/20
Fly Intel: Top five analyst initiations
02/21/20 Guggenheim
Guggenheim starts Guardant Health at Buy with addressable market seen expanding
02/21/20 Guggenheim
Guardant Health initiated with a Buy at Guggenheim
NSTG NanoString
$33.25 /

+1.91 (+6.09%)

12/04/19 Lake Street
Veracyte answered key question with NanoString pact, says Lake Street
11/14/19 Stifel
NanoString initiated with a Buy at Stifel
TXG 10x Genomics
$66.25 /

+0.925 (+1.42%)

03/05/20 Guggenheim
10x Genomics initiated with a Buy at Guggenheim
02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/06/20 Citi
10x Genomics initiated with a Buy at Citi
Initiation
10x Genomics initiated with a Buy at Guggenheim » 06:10
03/05/20
03/05
06:10
03/05/20
06:10
TXG

10x Genomics

$77.00 /

+0.54 (+0.71%)

Guggenheim analyst David…

Guggenheim analyst David Wastenberg initiated coverage of 10x Genomics with a Buy rating and $96 price target.

ShowHide Related Items >><<
TXG 10x Genomics
$77.00 /

+0.54 (+0.71%)

02/19/20 JPMorgan
10x Genomics price target raised to $95 from $65 at JPMorgan
01/09/20 JPMorgan
Danaher, Thermo named JPMorgan's top 2020 picks in Life Science Tools
01/06/20 Citi
10x Genomics initiated with a Buy at Citi
10/07/19 JPMorgan
10x Genomics initiated with an Overweight rating at JPMorgan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.